(Natural News) The results of a new pilot study showed the efficacy of lipoic acid in the reduction of whole brain atrophy among patients with secondary progressive multiple sclerosis (SPMS) compared with recently approved FDA drug ocrelizumab (brand name Ocrevus). In a randomized, double-blind study, researchers found that a daily dose of 1,200 mg of... |
from NaturalNews.com http://ift.tt/2gNu43J
No comments:
Post a Comment